<DOC>
	<DOCNO>NCT02008227</DOCNO>
	<brief_summary>This global , multicenter , open-label , randomize , control study evaluate efficacy safety Atezolizumab compare docetaxel patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) failure platinum-containing chemotherapy . Patients randomize 1:1 receive either docetaxel ( 75 mg/m2 intravenous infusion ) Atezolizumab ( 1200 mg intravenous infusion ) every three week . Treatment may continue long patient experience clinical benefit assess investigator , i.e. , absence unacceptable toxicity symptomatic deterioration attribute disease progression .</brief_summary>
	<brief_title>A Randomized Phase 3 Study Atezolizumab ( Engineered Anti-PDL1 Antibody ) Compared Docetaxel Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - `` OAK ''</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advanced metastatic ( Stage IIIB , Stage IV , recurrent ) nonsmall cell lung cancer ( NSCLC ) Representative formalinfixed paraffinembedded ( FFPE ) tumor specimens Disease progression follow treatment prior platinumcontaining regimen locally advance , unresectable/inoperable metastatic NSCLC disease recurrence within 6 month treatment platinumbased adjuvant/neoadjuvant regimen combine modality ( e.g. , chemoradiation ) regimen curative intent Measurable disease , define RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Known active untreated central nervous system ( CNS ) metastases Malignancies NSCLC within 5 year prior randomization , exception negligible risk metastasis death treat expect curative outcome History autoimmune disease History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia , evidence active pneumonitis screen chest CT scan . History radiation pneumonitis radiation field ( fibrosis ) permit . Active hepatitis B hepatitis C Prior treatment docetaxel Prior treatment CD137 agonist , antiCTLA4 , antiPD1 , antiPDL1 therapeutic antibody pathwaytargeting agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>